SecBot SecBot
SECBOTREPLAY Home › Report › TARS

TARS · Tarsus Pharmaceuticals announced a definitive agreement to acquire…

Tarsus Pharmaceuticals, Inc. · 8-K filed Aug 6, 2026 at 07:08 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 6, 2026 at 07:08 ET

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for ~$450M upfront ($270M cash + $180M stock) plus up to $350M in milestones and low-single-digit royalties on gildeuretinol net sales. Gildeuretinol is a Phase 3 oral therapy for Stargardt disease, a large inherited retinal disease with no FDA-approved therapy. The deal adds a potential blockbuster pipeline asset but carries significant execution risk given top-line data is not expected until H2 2029 and the upfront cash consideration represents a substantial portion of Tarsus's $2.6B market cap.

  • Tarsus to acquire Alkeus for ~$450M upfront ($270M cash + $180M stock at $61.38/share)
  • Up to $350M in additional milestone payments upon regulatory approval and first commercial sale
  • Low-single-digit tiered descending royalties on worldwide gildeuretinol net sales
  • Gildeuretinol is a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access